ResearcherNew York UniversityNo recent work listed

Salvatore Amodeo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0899-0534; OpenAlex author ID A5071335916. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2018: 1 paper

Papers 1

Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Co-author DOI 10.21037/jgo.2017.10.04 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Deirdre Jill Cohen · 1 shared paper, 2018 · strength 0.08
- Paper Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU… DOI 10.21037/jgo.2017.10.04 ↗
Marcovalerio Melis · 1 shared paper, 2018 · strength 0.08
- Paper Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU… DOI 10.21037/jgo.2017.10.04 ↗
Elliot Newman · 1 shared paper, 2018 · strength 0.08
- Paper Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU… DOI 10.21037/jgo.2017.10.04 ↗
Theresa M. Ryan · 1 shared paper, 2018 · strength 0.08
- Paper Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU… DOI 10.21037/jgo.2017.10.04 ↗
Howard S. Höchster · 1 shared paper, 2018 · strength 0.08
- Paper Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU… DOI 10.21037/jgo.2017.10.04 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.